Polyrizon enters into gmp manufacturing agreement for ctm supply of its pl-14 allergy blocker in preparation for planned 2025 clinical trial

The engagement with an eu-based gmp manufacturing facility enables timely production and preparation for clinical trial. the eu-based gmp manufacturer has large-scale commercial production capabilities, to support polyrizon in future commercialization efforts
PLRZ Ratings Summary
PLRZ Quant Ranking